唾液腺癌的预后标志物及其对生存的影响。

Prognostic markers in salivary gland cancer and their impact on survival.

机构信息

Department of Head and Neck Surgery, Poznan University of Medical Sciences, Greater Poland Cancer Center, Poznan, Poland.

Department of Cancer Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Center, Poznan, Poland.

出版信息

Head Neck. 2019 Sep;41(9):3338-3347. doi: 10.1002/hed.25857. Epub 2019 Jun 27.

DOI:10.1002/hed.25857

PMID:31246357

Abstract

BACKGROUND

The role of molecular markers in salivary gland carcinoma (SGC) is not well understood. We evaluated molecular marker expression and their prognostic value.

METHODS

Immunohistochemical analysis of 124 tumor specimens was performed to determine expression of androgen (AR), estrogen (ER), and progesterone (PR) receptors and epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), programmed death ligand 1 receptor (PD-L1), and PD-L1 in tumor-infiltrating mononuclear cell (TIMC). Survival outcomes (disease-free survival [DFS] and overall survival [OS]), pT and N classification, margin status, and treatment failure were assessed.

RESULTS

Most patients (78; 62.9%) had early-stage SGC. AR positivity and EGFR positivity were detected in 21.0% and 78.6%, respectively, of tumors. AR positivity and PD-L1 negativity were associated with locally advanced disease. PD-L1-negativity was associated with higher recurrence (38.5% vs 0%; P < .001) and worse DFS. OS and DFS were worse in patients with AR+ or HER2+ disease.

CONCLUSIONS

Several molecular markers-AR and HER2 positivity and PD-L1 negativity-were associated with worse clinical outcomes. Prospective, multi-institutional trials are needed to determine the prognostic value of these markers.

摘要

背景

目前对于唾液腺癌（SGC）中分子标志物的作用还不甚清楚。本研究旨在评估分子标志物的表达及其预后价值。

方法

对 124 例肿瘤标本进行免疫组化分析，以确定雄激素（AR）、雌激素（ER）和孕激素（PR）受体、表皮生长因子受体（EGFR）、人表皮生长因子受体 2（HER2）、程序性死亡配体 1 受体（PD-L1）和肿瘤浸润单核细胞（TIMC）中的 PD-L1 的表达。评估了生存结局（无病生存[DFS]和总生存[OS]）、pT 和 N 分类、切缘状态和治疗失败情况。

结果

大多数患者（78 例；62.9%）为早期 SGC。AR 阳性和 EGFR 阳性分别在 21.0%和 78.6%的肿瘤中检测到。AR 阳性和 PD-L1 阴性与局部晚期疾病相关。PD-L1 阴性与更高的复发率（38.5%比 0%；P < 0.001）和较差的 DFS 相关。AR+或 HER2+疾病患者的 OS 和 DFS 更差。